International Flavors & Fragrances
IFF
$83.61
-0.52%
International Flavors & Fragrances Inc. (IFF) is the world's largest specialty ingredients producer, supplying flavors, fragrances, health and biosciences, and food ingredients to industries including food, beverage, personal care, and pharmaceuticals. As a market leader in taste and scent, IFF leverages its proprietary formulations and global scale to maintain a competitive edge, while its health and biosciences segment is a top player in probiotics and enzymes. The current investor narrative centers on the company's strategic portfolio reshaping—including the planned divestiture of its food ingredients business expected to close in 2027—and its recent financial recovery after a challenging period marked by impairments and restructuring. With a 31.8% one-year stock price gain and a strong buy consensus from analysts, IFF is attracting attention as a turnaround story with improving profitability and a clearer focus on higher-margin segments.…
IFF
International Flavors & Fragrances
$83.61
Related headlines
Investment Opinion: Should I buy IFF Today?
Rating: Buy. IFF is a compelling turnaround play with a strong analyst consensus (Buy, mean 1.75) and an average target of $95.66, implying ~10.8% upside. The thesis rests on improving profitability, a strategic divestiture that should streamline operations, and a valuation that is undemanding relative to peers. Supporting evidence includes a PS ratio of 1.58x versus the industry's 2.58x (39% discount), Q1 2026 EPS of $0.66 versus a loss a year ago, a forward PE of 21.8x based on estimated EPS of $4.86, and a PEG ratio of 0.18, suggesting growth is undervalued. The stock has outperformed the S&P 500 by 13.1 percentage points over the past year, reflecting positive momentum. Risks include revenue contraction, high leverage, and execution risk on the divestiture. This Buy would be downgraded to Hold if revenue growth fails to stabilize or if the divestiture is delayed beyond 2027; it would be upgraded if the company demonstrates consistent organic growth and margin expansion. Overall, IFF appears undervalued relative to its history and peers, offering a favorable risk/reward for investors with a 12-24 month horizon.
Sign up to view all
IFF 12-Month Price Forecast
The AI model leans bullish on IFF due to its compelling valuation, improving profitability, and strategic portfolio reshaping. The 39% discount to peers on sales and the strong analyst support provide a favorable risk/reward. However, the persistent revenue decline and high leverage warrant caution. If the company can stabilize revenue and execute the divestiture smoothly, the stock could re-rate higher. Conversely, any setback in the turnaround would likely lead to a downgrade to neutral. Key developments to watch include quarterly revenue trends, margin performance, and divestiture announcements.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on International Flavors & Fragrances's 12-month outlook, with a consensus price target around $95.66 and implied upside of +14.4% versus the current price.
Average Target
$95.66
0 analysts
Implied Upside
+14.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$76 - $105
Analyst target range
The target price range spans from a low of $76.00 to a high of $105.00, with the high target suggesting a potential upside of 21.6% from current levels, likely pricing in successful execution of the food ingredients divestiture and margin expansion. The low target implies a downside of 12.0%, which could materialize if the company faces integration challenges or a prolonged demand slump. The spread between the high and low targets is $29, or about 30% of the average target, indicating moderate uncertainty. Given the recent upgrades and the strong buy consensus, the risk/reward profile appears favorable, but investors should monitor the divestiture progress and quarterly earnings for confirmation of the recovery trajectory.
Bulls vs Bears: IFF Investment Factors
IFF presents a classic turnaround opportunity with improving profitability, a strategic portfolio reshaping, and a compelling valuation discount. The bull case is supported by a strong analyst consensus, a 39% PS discount to peers, and a clear path to higher-margin growth through the Health & Biosciences segment. However, revenue contraction, negative trailing earnings, and high leverage temper enthusiasm. Currently, the bull case has stronger evidence given the tangible Q1 profit recovery and the potential for the divestiture to unlock significant value. The central tension is whether the company can sustain margin expansion and return to revenue growth while executing a complex divestiture—if it stumbles, the stock could fall to the low target, but success could drive it toward the high target.
Bullish
- Strong Buy consensus with 10.8% upside: 18 analysts rate IFF a Buy (mean 1.75) with an average target of $95.66, implying ~10.8% upside from $86.35. The high target of $105 suggests 21.6% potential, reflecting confidence in the turnaround.
- PS ratio 39% below industry average: IFF trades at 1.58x sales versus the industry average of 2.58x EV/Sales, a ~39% discount. This undervaluation is notable given its market leadership and improving profitability, offering a margin of safety.
- Q1 2026 profitability recovery: Q1 2026 EPS was $0.66 with net income of $169M, a sharp turnaround from the -$3.98 EPS loss in Q1 2025 (which included a $1.3B impairment). Operating margin improved to 10.2% from -31.8% a year ago.
- Strategic divestiture to unlock value: Planned divestiture of the Food Ingredients business (expected to close 2027) should streamline operations, reduce debt, and focus on higher-margin segments like Health & Biosciences, which generates 30% of profits.
Bearish
- Revenue declining year-over-year: Q1 2026 revenue fell 3.6% YoY to $2.741B from $2.843B, continuing a multi-quarter downtrend from $2.925B in Q3 2024. Organic growth remains elusive, partly due to divestitures and soft demand.
- Negative trailing EPS and thin margins: TTM EPS is -$0.02, and net margin is -3.3%. While Q1 was profitable, the trailing twelve months still show losses, indicating the recovery is fragile and not yet fully established.
- High leverage and interest burden: Debt-to-equity is 0.47, and interest expense was $44M in Q1 2026. EV/EBITDA at 29.9x is elevated, suggesting the market is pricing in significant future earnings growth that may not materialize.
- Potential downside to analyst low target: The low analyst target of $76 implies 12% downside from current levels. If the divestiture faces delays or demand weakens further, the stock could retreat toward that level.
IFF Technical Analysis
IFF's price trend over the past year has been a robust uptrend, with the stock gaining 31.77% over the last 12 months, significantly outperforming the S&P 500's 18.65% return. The current price of $86.35 sits near the upper end of its 52-week range, at approximately 96.7% of the range (calculated from a low of $59.14 and high of $89.32). This positioning near the highs suggests strong momentum, though it also raises the risk of overextension, especially after a 19.73% maximum drawdown from recent peaks. The stock's beta of 0.953 indicates slightly lower volatility than the broader market, providing some cushion in turbulent conditions.
Beta
0.95
0.95x market volatility
Max Drawdown
-19.7%
Largest decline past year
52-Week Range
$59-$89
Price range past year
Annual Return
+26.0%
Cumulative gain past year
| Period | IFF Return | S&P 500 |
|---|---|---|
| 1m | -0.3% | -1.1% |
| 3m | +6.8% | +3.0% |
| 6m | +20.1% | +15.4% |
| 1y | +26.0% | +16.2% |
| ytd | +22.9% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IFF Fundamental Analysis
IFF's revenue trajectory shows a mixed but stabilizing picture. In Q1 2026 (ending March 31, 2026), revenue was $2.741 billion, down 3.59% year-over-year from $2.843 billion in Q1 2025, but up sequentially from $2.589 billion in Q4 2025. The multi-quarter trend reveals a decline from $2.925 billion in Q3 2024 to $2.741 billion in Q1 2026, indicating a gradual contraction, though the pace has slowed. Segment data for Q1 2026 shows Food Ingredients leading at $839 million, followed by Taste at $656 million, Scent at $651 million, and Health & Biosciences at $595 million. The revenue decline is partly due to portfolio divestitures and softer demand in certain end markets, but the company is focusing on higher-growth areas like health and biosciences, which is expected to drive future expansion.
Quarterly Revenue
$2.7B
2026-03
Revenue YoY Growth
-3.6%
YoY Comparison
Gross Margin
37.1%
Latest Quarter
Free Cash Flow
$398000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IFF Overvalued?
Given IFF's trailing twelve-month net income is negative (EPS of -$0.02), the price-to-sales (PS) ratio is the most appropriate valuation metric, as PE ratios are not meaningful for loss-making companies. The current PS ratio is 1.58x, which is significantly lower than the industry average of 2.58x (based on EV/Sales of 2.58), indicating a discount of approximately 39%. This discount is notable given IFF's leading market position and improving profitability, suggesting the market may be undervaluing its earnings power. The forward PE of 21.83x implies that analysts expect a substantial earnings recovery, with estimated EPS of $4.86 for the next fiscal year, which would justify a higher valuation if achieved.
PE
-46.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~340x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: IFF's balance sheet carries significant debt (debt-to-equity 0.47), and interest expense of $44M in Q1 2026 eats into earnings. The company's trailing twelve-month net income is negative (EPS -$0.02), reflecting past impairments and restructuring charges. Revenue has declined for five consecutive quarters, from $2.925B in Q3 2024 to $2.741B in Q1 2026, indicating persistent top-line pressure. Operating margin, while improved to 10.2% in Q1, is still below historical norms, and the company's reliance on cost cuts rather than organic growth raises sustainability concerns. Free cash flow of $398M TTM is positive but modest relative to debt service requirements.
FAQ
The key risks include: (1) Financial risk from high debt (debt-to-equity 0.47) and negative trailing EPS, which could limit financial flexibility; (2) Operational risk from continued revenue decline (-3.6% YoY in Q1 2026), which may indicate structural challenges; (3) Execution risk on the planned divestiture of the Food Ingredients business, which could face regulatory or buyer-related delays; and (4) Market risk from high short interest (8.9 days to cover) and potential volatility, as seen in the 19.7% max drawdown over the past year. The most severe risk is a combination of revenue contraction and margin compression, which could drive the stock down to the $76 low target.
Analysts are bullish on IFF, with an average target of $95.66 and a high of $105, implying upside of 10.8% to 21.6% from the current price of $86.35. The base case scenario (50% probability) sees the stock trading in the $85-95 range over the next 12 months, driven by gradual recovery and successful divestiture execution. The bull case (30% probability) targets $95-105, while the bear case (20% probability) could see the stock fall to $76-85 if the turnaround stalls. The most likely outcome is a gradual appreciation toward the average target, supported by improving profitability and strategic focus.
Based on the price-to-sales ratio of 1.58x versus the industry average of 2.58x, IFF is undervalued by approximately 39%. The forward PE of 21.8x is reasonable given the expected EPS recovery to $4.86, and the PEG ratio of 0.18 suggests the stock is cheap relative to its growth prospects. The market appears to be pricing in a successful turnaround but not giving full credit for the potential margin expansion and divestiture benefits. Compared to its own history, the stock is trading near the upper end of its 52-week range, but the valuation metrics indicate that the market is not overpaying for the company's improving fundamentals.
IFF appears to be a good buy for investors with a 12-24 month horizon, given the strong analyst consensus (Buy) and average target of $95.66, implying ~10.8% upside. The stock trades at a 39% discount to its industry on a price-to-sales basis, and Q1 2026 showed a clear earnings recovery (EPS $0.66 vs -$3.98 a year ago). However, the biggest downside risk is continued revenue decline, which could push the stock toward the $76 low target. For risk-tolerant investors seeking a turnaround story with a margin of safety, IFF is a compelling buy, but those with low risk tolerance may prefer to wait for evidence of sustained organic growth.
IFF is better suited for long-term investment (3-5 years) given its turnaround nature and the expected benefits from the divestiture, which won't close until 2027. The stock has a beta of 0.95, indicating market-like volatility, and a dividend yield of 2.4%, providing some income while waiting for capital appreciation. Short-term trading is possible given the stock's momentum, but the high short interest and potential for earnings-driven swings make it risky. For investors seeking to benefit from the company's strategic transformation and margin expansion, a minimum holding period of 12-24 months is recommended to allow the thesis to play out.